Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

This is a one-year pilot, interventional, prospective, single arm, non-randomized, multicentric (3 centers) controlled study that aims to evaluate the response of type 3 choroidal neovascularization to treatment by Aflibercept following a classic protocol.

Inclusion Criteria:

• Males or females aged more than 50 years
• Patients with type 3 choroidal neovascularization assessed on FA, ICG and OCT
• Exudation on SD-OCT scans defined by intraretinal cysts or subretinal fluid.
• Best Corrected Visual Acuity at inclusion between 24 and 78 letters (ETDRS)
• Media clarity, pupillary dilation and patient cooperation sufficient to allow fundus photographs of adequate quality

Exclusion Criteria:

• Any contraindications as reported in the labelling of Aflibercept (Eylea®): Ocular or periocular infection, Active intraocular inflammation or Hypersensitivity.
• Any previous history of intravitreal injections in the study eye for exudative AMD
• Any secondary chorioretinal anastomosis due to retinal scar or fibrosis
• Any history of vitrectomy
• Media opacities preventing accurate imaging of the retina (cataract)
• Any other retinal disorder possibly associated with type 3 CNV (epiretinal membrane, macular hole)
• Confirmed intraocular pressure ≥25 mmHg or non-stable glaucoma.